| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| Other Sizes |
| Targets |
As an N-acyl amino acid, (Cyclohexanecarbonyl)-L-leucine may target enzymes that recognize N-acylated amino acids, such as aminoacylases or peptidases. When incorporated into larger peptides, the cyclohexanecarbonyl group can modulate interactions with hydrophobic binding pockets of receptors or enzymes. However, as a building block, it does not have a defined primary biological target. It is classified as an Amino Acid Derivative with a target pathway in "Others."
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
The compound has no direct in vitro biological activity. It is used as a chemical intermediate rather than a test article. Any biological activity would require incorporation into a peptide or drug candidate. No IC50 or EC50 values for the parent compound are available. It may be used in studies of enzyme-substrate specificity for N-acyl amino acid hydrolases. |
| ln Vivo |
No in vivo activity data are available. (Cyclohexanecarbonyl)-L-leucine has not been tested in animal models for efficacy. Its use is limited to ex vivo peptide synthesis and characterization. For peptides derived from this building block, downstream in vivo studies (e.g., in models of inflammation, cancer, or metabolic disease) may be performed, but no such data exist for the parent compound.
|
| Enzyme Assay |
The compound is not used in enzyme/receptor binding assays. Instead, standard chemical protocols apply: HPLC analysis using a C18 reverse-phase column with UV detection at 220 nm. Mobile phase: acetonitrile/water with 0.1% TFA (gradient 20-80% over 20 minutes). For characterization, ¹H NMR and ¹3C NMR in CDCl3 or DMSO-d₆ are used. No biological binding protocols exist.
|
| Cell Assay |
No cell-based protocols are established for this N-acyl leucine. For downstream peptides, a typical protocol involves seeding target cells (e.g., cancer or immune cells) in 96-well plates, treating with the synthesized peptide (0.1-100 uM) for 24-72 hours, and assessing viability, apoptosis, or cytokine production. This intermediate is not used in cell assays.
|
| Animal Protocol |
No animal experiments have been conducted with this compound. For peptides synthesized using this building block, in vivo studies might involve administration in mice (e.g., intravenous, intraperitoneal, or oral) for pharmacokinetic or efficacy evaluation in disease models. No such data are available for the N-acyl leucine itself.
|
| ADME/Pharmacokinetics |
No pharmacokinetic data are available for (Cyclohexanecarbonyl)-L-leucine. As an N-acyl amino acid, it might be absorbed orally (MW 241.33, logP ~2-3). It could be subject to hydrolysis by aminoacylases or peptidases in the gut and liver, releasing free leucine. No ADME studies (half-life, bioavailability, clearance) have been reported. The compound is stable as a solid at 4degC to -20degC.
|
| Toxicity/Toxicokinetics |
The safety profile: May cause skin and eye irritation. Harmful if swallowed (oral LD50 >2000 mg/kg predicted). Not classified as carcinogen or reproductive toxin. Use standard PPE (gloves, goggles, lab coat). Avoid inhalation of dust. In case of contact, flush with water. The compound is supplied as a solid with purity >97% and is stable under dry, cool storage conditions.
|
| References | |
| Additional Infomation |
(Cyclohexanecarbonyl)-L-leucine is not an approved drug and has no clinical trial history. It is a research chemical exclusively for peptide synthesis and medicinal chemistry. Its value lies in the bulky hydrophobic cyclohexanecarbonyl group, which can be used to influence peptide conformation and membrane permeability. This compound is often employed in the design of bioactive peptides, protease-resistant peptidomimetics, and drug delivery systems. It is commercially available for research use only and is not intended for human therapeutic applications.
|
| Molecular Formula |
C13H23NO3
|
|---|---|
| Molecular Weight |
241.33
|
| Exact Mass |
241.168
|
| CAS # |
157116-68-2
|
| PubChem CID |
9992929
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.022
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
17
|
| Complexity |
270
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O=C(C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])N([H])[C@]([H])(C(=O)O[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H]
|
| InChi Key |
MJOSQGRPLTUAHR-NSHDSACASA-N
|
| InChi Code |
InChI=1S/C13H23NO3/c1-9(2)8-11(13(16)17)14-12(15)10-6-4-3-5-7-10/h9-11H,3-8H2,1-2H3,(H,14,15)(H,16,17)/t11-/m0/s1
|
| Chemical Name |
(2S)-2-(cyclohexanecarbonylamino)-4-methylpentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.1437 mL | 20.7185 mL | 41.4370 mL | |
| 5 mM | 0.8287 mL | 4.1437 mL | 8.2874 mL | |
| 10 mM | 0.4144 mL | 2.0719 mL | 4.1437 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
